Tailored eradication vs empirical bismuth-containing quadruple therapy for first-line Helicobacter pylori eradication: A comparative, open trial

Table 1 Baseline characteristics of the study population

	Tailored therapy using DPO-PCR (n = 50)	Empirical bismuth-based quadruple therapy (n = 104)	P value
Age, mean ± SD (yr)	58.3 ± 13.9	57.4 ± 11.6	0.3
Men, n (%)	30 (60.0)	56 (53.8)	0.5
Smoking, n (%)	13 (26.0)	17 (16.3)	0.2
Drinking, n (%)	16 (32.0)	34 (32.7)	0.8
Comorbidity
Hypertension, n (%)	11 (22.0)	31 (29.8)	0.4
Diabetes mellitus, n (%)	11 (22.0)	17 (16.3)	0.5
Cardiovascular disease, n (%)	2 (4.0)	6 (5.8)	0.6
Reasons for eradication, n (%)
Peptic ulcer disease	37 (64.0)	28 (26.9)	0.002
Post ESD due to EGC	8 (16.0)	3 (2.9)	0.003
Post ESD due to adenoma	5 (10.0)	2 (1.9)	0.024
MALToma	2 (4.0)	0 (0.0)	0.04
Chronic atrophic gastritis with intestinal metaplasia	2 (4.0)	71 (68.3)	< 0.001
Nodular gastritis	3 (6.0)	0 (0.0)
Clarithromycin resistance diagnosed by DPO-PCR, n (%)		Non available
No	37 (74.0)
A2142G positive	1 (2.0)
A2143G positive	12 (24.0)

DPO-PCR: Dual priming oligonucleotide polymerase chain reaction; ESD: Endoscopic submucosal dissection; EGC: Early gastric cancer; MALToma: Mucosa associated lymphoid tissue lymphoma.